Excess Mortality With Alzheimer Disease and Related Dementias as an Underlying or Contributing Cause During COVID-19

AI SummaryThis study compares COVID-19 pandemic-era excess deaths related to Alzheimer’s disease or dementia between two years, looking at various factors.This cross-sectional study compares COVID-19 pandemic-era excess deaths associated with Alzheimer disease or related dementias between year 1 and year 2 overall and by age, sex, race and ethnicity, and place of death.

Amyloid-β (Aβ) immunotherapy induced microhemorrhages are associated with activated perivascular macrophages and peripheral monocyte recruitment in Alzheimer’s disease mice

Amyloid-related imaging abnormalities (ARIA) have been identified as the most common and serious adverse events resulting from pathological changes in the cerebral vasculature during several recent anti-amyloi…

Oleoylethanolamide facilitates PPARα and TFEB signaling and attenuates Aβ pathology in a mouse model of Alzheimer’s disease

AI SummaryAge is the primary risk factor for Alzheimer’s disease. Along with the presence of certain brain abnormalities, recent findings suggest that inflammation and immune dysfunction may also contribute to the development of the disease.Age is the strongest risk factor for the development of Alzheimer’s disease (AD). Besides the pathological hallmarks of β-amyloid (Aβ) plaques… Continue reading Oleoylethanolamide facilitates PPARα and TFEB signaling and attenuates Aβ pathology in a mouse model of Alzheimer’s disease

Current views on meningeal lymphatics and immunity in aging and Alzheimer’s disease

AI SummaryAlzheimer’s disease is a type of dementia that occurs with age and is linked to the build-up of amyloid beta and neurofibrillary tangles in the brain.Alzheimer’s disease (AD) is an aging-related form of dementia associated with the accumulation of pathological aggregates of amyloid beta and neurofibrillary tangles in the brain. These phenomena are accompani…

Neuronal γ-secretase regulates lipid metabolism, linking cholesterol to synaptic dysfunction in Alzheimer’s disease

AI SummaryThe authors suppressed γ-secretase in human neurons and observed changes in synaptic activity and number. They found that γ-secretase regulates neurotransmitter release through the regulation of cholesterol levels.Essayan-Perez and Südhof chronically suppressed γ-secretase in human-induced neurons to record their synaptic activity and image their synapses. They show that γ-secretase regulates the probability of neurotransmitter… Continue reading Neuronal γ-secretase regulates lipid metabolism, linking cholesterol to synaptic dysfunction in Alzheimer’s disease

Error in Abstract

The Original Investigation titled “Mitigating the Associations of Kidney Dysfunction With Blood Biomarkers of Alzheimer Disease by Using Phosphorylated Tau to Total Tau Ratios,” published May 8, 2023, was corrected to change “higher eGFR” to “lower eGFR” in the second sentence of the Results section of the abstract.

Cholinesterase Inhibitors for Treatment of Psychotic Symptoms in Alzheimer Disease and Parkinson Disease

AI SummaryThis meta-analysis investigates the effectiveness of cholinesterase inhibitors in treating psychotic symptoms in patients with Alzheimer’s disease, Parkinson’s disease, and dementia with Lewy bodies.This meta-analysis examines the use of cholinesterase inhibitors as treatment of psychotic symptoms in patients with Alzheimer disease, Parkinson disease, and dementia with Lewy bodies.